Obesity-drug rollout dynamics
- The GLP-1 obesity-drug market is broadening, with oral formulations and manufacturing capacity becoming central issues. - Eli Lilly's oral drug Foundayo recorded 1,390 prescriptions in its debut week while Novo Nordisk leads manufacturing expansion. - Rising competition, side-effect concerns, and supply constraints mean route of administration and capacity will shape market shares. (medicaldialogues.in) (thehindubusinessline.com)
Eli Lilly’s new obesity pill, Foundayo, logged 1,390 U.S. prescriptions in its first tracked week, putting the market’s next fight on pills and supply. (finance.yahoo.com) Reuters reported the 1,390 figure for the week ended April 10, citing IQVIA data. Novo Nordisk’s oral Wegovy reached 3,071 U.S. prescriptions in its first four days after its January 5 launch. (finance.yahoo.com) Foundayo won U.S. Food and Drug Administration approval on April 1 for adults with obesity, or overweight with weight-related medical problems. Lilly said shipping began April 6 through LillyDirect, with self-pay pricing starting at $149 a month for the lowest dose. (investor.lilly.com) These drugs mimic gut hormones that curb appetite and slow digestion. Pills change the pitch because they avoid needles, refrigeration, and injection training, which obesity specialists told Reuters has pulled in first-time GLP-1 users. (investor.lilly.com) (medicaldialogues.in) Route of administration is now part of the competition. Lilly says Foundayo can be taken any time of day without food or water restrictions, while Reuters reported Novo’s Wegovy pill must be taken first thing in the morning and 30 minutes before food, water, or other medicines. (investor.lilly.com) (medicaldialogues.in) The bigger bottleneck is manufacturing. Novo Nordisk said in its 2025 annual report that it is expanding direct-to-patient access in the U.S. while scaling supply, and a trade report citing that filing said Novo planned about $9 billion in 2025 capital spending to add capacity across active ingredient, aseptic production, finished production, and packaging. (annualreport.novonordisk.com) (pharmamanufacturing.com) Novo’s annual report said the company completed the Catalent site deal in late 2024 and is expanding facilities in Denmark, France, Brazil, China, and the U.S. The same report said Novo’s production network is operating around the clock and that demand has stretched capacity. (pharmamanufacturing.com) Lilly is building, too. Reuters reported this month that Lilly plans to invest $3 billion over the next decade in China to expand supply-chain capacity and production for orforglipron, the molecule sold as Foundayo. (medicaldialogues.in) Safety and tolerability are still part of the rollout. Lilly’s approval announcement said the most common adverse reactions were gastrointestinal, and Reuters reported on April 15 that the Food and Drug Administration asked Lilly for additional post-marketing data on liver injury, cardiovascular risk, and delayed gastric emptying; Lilly said late-stage testing showed no indication of liver damage. (investor.lilly.com) (medicaldialogues.in) Novo’s scale remains large even as Lilly presses in. Novo Nordisk said 2025 obesity-care sales rose 26% in Danish kroner to DKK 82.3 billion, and that it held 59.6% of the global branded obesity-market volume. (annualreport.novonordisk.com) The next few quarters will show whether patients pick the pill that is easier to take, the brand that is easier to find, or the company that can keep pharmacies stocked. (finance.yahoo.com) (pharmamanufacturing.com)
